Publications by authors named "Hanamura T"
A woman with a single coronary artery underwent aortic valve replacement due to aortic stenosis. Two years later, she developed an aortic annular abscess around the right coronary cusp and non-coronary cusp. Significant adhesions to the right coronary artery (RCA) resulted from the abscess, making artery separation challenging, and raising concerns about potential future RCA stenosis.
View Article and Find Full Text PDFObjective: Obesity adversely impacts breast cancer treatment and outcomes. This study assessed the efficacy of nurses' motivational interviews (MI) in promoting weight loss among breast cancer patients.
Methods: Motivational Interviewing was performed at 4, 8, and 12 weeks from baseline in 27 overweight/ obese breast cancer patients receiving adjuvant endocrine therapy.
Some cases of left ventricular pseudoaneurysms (LVPAs) are asymptomatic. While cardiac magnetic resonance imaging is important, a chest x-ray can easily be performed and is also crucial for the detection of LVPA during the first outpatient visit.
View Article and Find Full Text PDFBackground: Alpha-2-glycoprotein 1, zinc-binding (ZAG), a secreted protein encoded by the AZGP1 gene, is structurally similar to HLA class I. Despite its presumed immunological function, little is known about its role in tumor immunity. In this study, we thus aimed to determine the relationship between the expression of AZGP1/ZAG and the immunological profiles of breast cancer tissues at both the gene and protein level.
View Article and Find Full Text PDFAtaxia Telangiectasia in a Patient with Breast Cancer: A Case Report.
Tokai J Exp Clin Med
September 2023
Ataxia telangiectasia (AT) is a rare autosomal recessive disorder caused by the pathological variants of the gene. Owing to i ts r arity a nd n ature, complications of AT, such a s malignant tumors, a re often difficult to manage with standard imaging studies and treatments, and there are no established management strategies. We report the case of a woman who had AT in childhood and developed breast cancer in her 20s; the disease was successfully managed by the decision-making of multidisciplinary physicians professionals with ethics support.
View Article and Find Full Text PDFArticle Synopsis
- - The study investigates how hormone receptors (estrogen, progesterone, and androgen) influence immune responses in breast cancer, aiming to find new treatment strategies.
- - Using data from METABRIC and SCAN-B, researchers found that estrogen and androgen receptor levels were associated with lower immune cell presence in breast cancer tissue, particularly affecting T cells and macrophages.
- - Results indicate that higher expression of hormone receptors correlates with specific immune profiles, suggesting a complex interaction that could inform therapeutic approaches targeting breast cancer immunity.
Article Synopsis
- * The research included 103 MBC patients diagnosed over a decade, revealing insights such as a median age of 71, high rates of hormone receptor positivity, and BRCA2 mutations among the tumors.
- * Findings suggested a need for tailored treatment strategies for MBC in Japan, as there are notable differences compared to Western countries, with survival rates of 64.4% for recurrence-free and 54.3% for overall survival over five years.
Article Synopsis
- - Breast cancer is a common type of cancer in women and can spread to various parts of the body, with gastrointestinal tract metastasis being rare.
- - Invasive lobular carcinoma, a less common form of breast cancer, has a higher likelihood of metastasizing to the gastrointestinal tract compared to invasive ductal carcinoma.
- - The text discusses a rare case of invasive lobular carcinoma that extensively metastasized to the colonic mucosa and highlights the potential increase in rare metastatic diseases due to better survival rates from current treatments.
An 81-year-old man was admitted for general fatigue of one month's duration. Two sets of blood cultures revealed bacteremia, due to Pasteurella multocida, while computed tomography (CT) revealed a 47-mm descending aortic saccular aneurysm. After transfer to our hospital, the saccular aneurysm rapidly grew to 54 mm.
View Article and Find Full Text PDFTumor-infiltrating lymphocytes (TILs) and programmed cell death 1 ligand 1 (PD-L1) are established prognostic and predictive biomarkers for certain breast cancer subsets. However, their association with the immune response complexity is not fully understood. Therefore, we analyzed the association between the immune cell fractions in breast cancer tissues and histologically assessed TIL (hTIL) and PD-L1 (hPD-L1).
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the role of the CHIP protein, a ubiquitin ligase, in breast cancer, noting that lower levels of CHIP are linked to tumor progression and metastasis.
- Researchers analyzed RNA from 45 breast cancer samples, finding that CHIP mRNA levels were affected by DNA methylation in the promoter region, impacting tumor progression.
- The results suggest that methylation of a specific CpG in the CHIP gene is associated with poor long-term prognosis in estrogen receptor-positive breast cancer patients.
Article Synopsis
- - The study investigates the androgen receptor (AR) in breast cancer, suggesting that serum factors responsive to androgens could indicate tumor AR activity and serve as potential biomarkers.
- - Researchers identified a set of 163 dihydrotestosterone (DHT)-responsive genes in an AR-positive breast cancer model, focusing on genes encoding secreted proteins (PSA, ZAG, PIP) to assess their expression in various breast cancer cell lines.
- - Results showed that anti-androgen treatment reduced cell proliferation and that the secreted factors were regulated by AR activation, indicating their potential as serum biomarkers for measuring tumor AR activity across different breast cancer types.
Article Synopsis
- Triple-negative breast cancer (TNBC) has a high risk of recurrence shortly after diagnosis, with increased androgen receptor (AR) expression linked to more aggressive tumor behavior.
- In preclinical models, reducing AR levels or inhibiting its function decreased TNBC invasion, tumor growth, and recurrence rates, suggesting that AR plays a crucial role in TNBC survival and progression.
- The study also found a positive feedback loop between AR and the TGFβ signaling pathway, indicating that targeting both pathways may help lower recurrence rates and improve survival outcomes in TNBC patients.
Article Synopsis
- Mutations in the estrogen receptor alpha (ER) are found in over 40% of metastatic breast cancers that resist aromatase inhibitor therapy, indicating a shift in hormone dependency among these tumors.
- Metastases with mutant ER showed different immune cell profiles and hormone receptor levels compared to those with wild-type ER, pointing to a potential mechanism of survival beyond traditional hormone reliance.
- Targeting proteins associated with mutant ER tumors, such as androgen receptor (AR) and chitinase-3-like protein 1 (CHI3L1), may enhance the effectiveness of treatments like fulvestrant and open avenues for immunotherapy in patients with these mutations.
Background: Recent preclinical data suggest that androgen receptor (AR) signaling plays a significant role in subsets of breast cancer. Clinical trials testing AR-targeting therapies in breast cancer have been conducted. Assessment of AR-signal in breast cancer tissue maybe useful for treatment selections.
View Article and Find Full Text PDFWe previously reported the establishment of several types of long-term estrogen-depleted-resistant (EDR) cell lines from MCF-7 breast cancer cells. Type 1 EDR cells exhibited the best-studied mechanism of aromatase inhibitor (AI) resistance, in which estrogen receptor (ER) expression remained positive and PI3K signaling was upregulated. Type 2 EDR cells showed reduced ER activity and upregulated JNK-related signaling.
View Article and Find Full Text PDFEstrogen plays crucial roles in the progression of hormone-dependent breast cancers through activation of nuclear estrogen receptor α (ER). Estrogen is produced locally from circulating inactive steroids and adrenal androgens in postmenopausal women. However, conversion by aromatase is a rate-limiting step in intratumoral estrogen production in breast cancer.
View Article and Find Full Text PDFBackground/aims: Acerola (Malpighia emarginata DC.) is a fruit that is known to contain high amounts of ascorbic acid (AA) and various phytochemicals. We have previously reported that AA deficiency leads to ultraviolet B (UVB)-induced skin pigmentation in senescence marker protein 30 (SMP30)/gluconolactonase (GNL) knockout (KO) hairless mice.
View Article and Find Full Text PDFDifferent epigenetic mechanisms of ERα implicated in the fate of fulvestrant-resistant breast cancer.
J Steroid Biochem Mol Biol
March 2017
Approximately 70% of breast cancers express estrogen receptor α (ERα), which plays critical roles in breast cancer development. Fulvestrant has been effectively used to treat ERα-positive breast cancer, although resistance remains a critical problem. To elucidate the mechanism of resistance to fulvestrant, we established fulvestrant-resistant cell-lines named MFR (MCF-7 derived fulvestrant resistance) and TFR (T-47D derived fulvestrant resistance) from the ERα-positive luminal breast cancer cell lines MCF-7 and T-47D, respectively.
View Article and Find Full Text PDFArticle Synopsis
- Aromatase inhibitors (AIs) are commonly used to treat hormone receptor-positive postmenopausal breast cancer, but some patients either don't respond or experience recurrence due to various resistance mechanisms.
- This study identifies a new mechanism of resistance, involving the overexpression of steroid sulfatase (STS) and organic anion transporter peptides (OATPs) in letrozole-resistant (LR) breast cancer cell lines, which enhances cell proliferation in estrogen-depleted conditions.
- The findings suggest that targeting E1S metabolism through STS and OATPs could be a potential therapeutic strategy for tackling AI-resistant breast cancer.